What are the clinical manifestations of isoniazid (INH) psychosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Isoniazid-Induced Psychosis: Clinical Manifestations

Isoniazid-induced psychosis typically presents with delusions and/or hallucinations, often accompanied by visual hallucinations including bright colors and strange designs, with onset most commonly occurring within the first 2 months of treatment. 1, 2

Timing and Onset

  • Higher frequency of psychotic symptoms occurs during the first 2 months of isoniazid therapy, with relatively early onset observed in patients aged 18 years or younger 2
  • Acute presentations can manifest within 30 minutes to 3 hours after ingestion in overdose scenarios 1
  • Symptoms may appear as early as 3 days after initiating treatment in susceptible individuals 3

Core Psychotic Symptoms

Primary manifestations include:

  • Delusions and hallucinations are the most common presenting features 2
  • Visual hallucinations with bright colors and strange designs are characteristic early manifestations 1
  • Auditory hallucinations may also occur 2

Associated Neuropsychiatric Features

Beyond core psychotic symptoms, patients frequently exhibit:

  • Psychomotor disturbances 2
  • Disorganized speech or formal thought disorder 2
  • Disorganized or abnormal behavior 2
  • Sleep disturbances 2
  • Hostility or aggression 2
  • Confusion 2
  • Affective symptoms (mood changes, depression) 2, 4
  • Anxiety symptoms 2
  • Cognitive difficulties 2

Early Warning Signs in Mild Cases

  • Nausea and vomiting 1
  • Dizziness 1
  • Slurring of speech 1
  • Blurring of vision 1
  • Mood and behavioral changes including anorexia, apathy, and fatigue 4

Severe Presentations

In marked overdosage or severe toxicity:

  • Respiratory distress 1
  • CNS depression progressing from stupor to profound coma 1
  • Severe, intractable seizures 1
  • Severe metabolic acidosis 1

Critical Clinical Pearls

Key distinguishing features:

  • Awareness and level of consciousness typically remain intact in isoniazid-induced psychosis (unlike delirium), unless severe overdose has occurred 5
  • More than 80% of cases rechallenged with isoniazid resulted in recurrence of psychotic symptoms, confirming the causal relationship 2
  • The presentation can be acute and intense in patients without prior psychiatric history 6, 3

Risk Factors for Development

Predisposing factors include:

  • Slow acetylator status 7
  • Diabetes mellitus 4, 7
  • Hepatic insufficiency 7
  • Advanced age 7
  • Alcoholism 4, 7
  • Family or personal history of mental illness 7
  • Nutritional deficiency states 4

Mechanism and Pathophysiology

Two primary mechanisms explain the presentation:

  • Pyridoxine (vitamin B6) deficiency leading to decreased neurotransmitter synthesis, particularly serotonin 4, 7, 6
  • Direct isoniazid toxicity related to its chemical similarity to iproniazid, a powerful monoamine oxidase inhibitor 7

Clinical Course and Resolution

  • Symptoms typically resolve after isoniazid discontinuation, though complete resolution may require additional antipsychotic treatment 7, 6
  • Favorable evolution occurs after definitive cessation of isoniazid therapy 7
  • Patients may remain symptom-free long-term after appropriate management 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Criteria and Treatment Options for Psychotic Personality Traits

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Isoniazid-induced psychosis.

The Annals of pharmacotherapy, 1998

Research

[Behavioral disorders after treatment with isoniazid].

Bulletin de la Societe de pathologie exotique (1990), 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.